Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | MMP2 | P08253 | 13/20 | 0.51 |
| ▸ | MMP9 | P14780 | 5/20 | 0.51 |
| ▸ | MMP3 | P08254 | 10/20 | 0.49 |
| ▸ | MMP1 | P03956 | 10/20 | 0.47 |
| ▸ | MMP13 | P45452 | 8/20 | 0.47 |
| ▸ | MMP7 | P09237 | 7/20 | 0.47 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7795549 | 0.93 | MMP2 (0.51) | CA12CA1CA2CA9MMP2 | |
| SCHEMBL7805690 | 0.91 | MMP2 (0.63) | MMP2MMP9MMP3MMP1MMP13 | |
| SCHEMBL7804336 | 0.85 | CA12 (0.62) | CA12CA1CA2CA9MMP2 | |
| SCHEMBL7805720 | 0.82 | CA12 (0.57) | CA12CA1CA2CA9MMP2 | |
| SCHEMBL7803700 | 0.79 | CA12 (0.62) | CA12CA1CA2CA9MMP2 | |
| SCHEMBL7802263 | 0.77 | MMP1 (0.58) | CA12CA1CA2CA9MMP2 | |
| SCHEMBL7802259 | 0.77 | SMN1; SMN2 (0.45) | — | |
| SCHEMBL7802317 | 0.76 | MMP1 (0.67) | MMP2MMP9MMP3MMP1MMP13 | |
| SCHEMBL24979958 | 0.75 | MMP1 (0.63) | MMP2MMP9MMP3MMP1MMP13 | |
| SCHEMBL7795572 | 0.74 | MMP1 (0.61) | MMP2MMP9MMP3MMP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010056184-A1 | Pipecolinic acid derivatives, method of manufacturing the same and therapeutic agents containing these compounds | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2001-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056184-A1 | Pipecolinic acid derivatives, method of manufacturing the same and therapeutic agents containing these compounds | NCEH1, NOP10, HRH1 | CA12 1924/4885CA1 2344/4885CA2 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.